Evidence map›Paper›PMID 42158426›Full record

ArticleFrontiers in oncology2026

The

Marta Brunetti, Kristin Andersen, Geir Erland Tjønnfjord, Bernward Zeller, Signe Spetalen, Monica Cheng Munthe-Kaas, Liv Toril Nygård Osnes, Tina Treu Os, Francesca Micci

Abstract read
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Marta BrunettiSection for Cancer Cytogenetics, Department of Pathology, Oslo University Hospital, Oslo, Norway.
Kristin AndersenSection for Cancer Cytogenetics, Department of Pathology, Oslo University Hospital, Oslo, Norway.
Geir Erland TjønnfjordSection for Cancer Cytogenetics, Department of Pathology, Oslo University Hospital, Oslo, Norway.
Bernward ZellerDepartment of Pediatrics, Oslo University Hospital, Oslo, Norway.
Signe SpetalenInstitute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
Monica Cheng Munthe-KaasDepartment of Pediatrics, Oslo University Hospital, Oslo, Norway.
Liv Toril Nygård OsnesDepartment of Immunology, Oslo University Hospital, Oslo, Norway.
Tina Treu OsDepartment of Pediatrics, Oslo University Hospital, Oslo, Norway.
Francesca MicciSection for Cancer Cytogenetics, Department of Pathology, Oslo University Hospital, Oslo, Norway.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The World Health Organization classification of tumors of hematopoietic and lymphoid tissues recognizes acute erythroid leukemia as a distinct entity under myeloid neoplasms. Erythroblastic sarcoma, also known as extramedullary erythroid sarcoma, is defined as a rare extramedullary tumor composed of erythroid precursors, typically occurring outside the bone marrow. While both entities involve immature erythroid precursors and share similar histology, acute erythroid leukemia is a systemic marrow-based leukemia, whereas erythroblastic sarcoma is a localized mass-forming lesion. Since these entities can overlap morphologically with other clinically distinct myeloid malignancies and myelodysplastic syndrome, it is fundamental to characterize them genetically. Materials and methods: We report a rare and diagnostic challenging case of a 2-year-old boy with erythroid sarcoma characterized by extensive extramedullary involvement, including mediastinum, gastrointestinal tract, pleura/peritoneum, bilateral kidneys, and lymph nodes. Results and discussion: The patient achieved a sustained complete remission following standard acute myeloid leukemia-like therapy with consolidative allogenic stem cell transplant. An

Indexed as

erythroid leukemiaerythroid sarcomafusion geneNFIA::CBFA2T3pediatric leukemiat (1,16)(p31;q24)

Identifiers

PMID42158426
PMCPMC13181429

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.